RRML - Clinical applications of total PSA and free PSA tumor markers

Main page
News
RJLabM Credits
Archive
- Current issue
- Ahead of print
- List of published issues
- 2025
  - Nr.1/2025
  - Nr.2/2025
  - Nr.3/2025
- 2024
  - Nr.4/2024
  - Nr.3/2024
  - Nr.2/2024
  - Nr.1/2024
  - Supplement 1/2024
- 2023
  - Nr.4/2023
  - Nr.3/2023
  - Nr.2/2023
  - Nr.1/2023
  - Supplement 1/2023
- 2022
  - Nr.4/2022
  - Nr.3/2022
  - Nr.2/2022
  - Nr.1/2022
  - Supplement 1/2022
- 2021
  - Nr.4/2021
  - Nr.3/2021
  - Nr.2/2021
  - Nr.1/2021
- 2020
  - Nr.4/2020
  - Nr.3/2020
  - Nr.2/2020
  - Nr.1/2020
  - Supplement 1/2020
- 2019
  - Nr.4/2019
  - Nr.3/2019
  - Nr.2/2019
  - Nr.1/2019
  - Supplement 1/2019
- 2018
  - Nr.4/2018
  - Nr.3/2018
  - Nr.2/2018
  - Nr.1/2018
  - Supplement 1/2018
  - Supplement 2/2018
  - Supplement 3/2018
- 2017
  - Nr.4/2017
  - Nr.3/2017
  - Nr.2/2017
  - Nr.1/2017
  - Supplement 1/2017
- 2016
  - Nr.4/2016
  - Nr.3/2016
  - Nr.2/2016
  - Nr.1/2016
  - Supplement 1/2016
- 2015
  - Nr.4/2015
  - Nr.3/2015
  - Nr.2/2015
  - Nr.1/2015
  - Supplement 1/2015
- 2014
  - Nr.4/2014
  - Nr.3/2014
  - Nr.2/2014
  - Nr.1/2014
  - Supplement 1/2014
- 2013
  - Nr.4/2013
  - Nr.3/2013
  - Nr.2/2013
  - Nr.1/2013
  - Supplement 1/2013
- 2012
  - Nr.4/2012
  - Nr.3/2012
  - Nr.2/2012
  - Nr.1/2012
  - Supplement 1/2012
- 2011
  - Nr.4/2011
  - Nr.3/2011
  - Nr.2/2011
  - Nr.1/2011
  - Supplement 1/2011
- 2010
  - Nr.4/2010
  - Nr.3/2010
  - Nr.2/2010
  - Nr.1/2010
  - Supplement 1/2010
- 2009
  - Nr.4/2009
  - Nr.3/2009
  - Nr.2/2009
  - Nr.1/2009
  - Supplement 1/2009
- 2008
  - Nr.4/2008
  - Nr.3/2008
  - Nr.2/2008
  - Nr.1/2008
  - Supplement 1/2008
- 2007
  - Nr.4/2007
  - Nr.3/2007
  - Nr.2/2007
  - Nr.1/2007
- 2006
  - Nr.4/2006
  - Nr.3/2006
  - Nr.2/2006
  - Nr.1/2006
- 2005
  - Nr.1/2005
Instructions for authors
Online applications
- Send an article
- Online payments
Editorial
About us
Links

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Top 10 downloaded articles - September 2025 -

Romanian Review of Laboratory ...	14
ATM rs189037 polymorphism: A p...	9
The diagnostic value of lipopr...	9
Assessment of preoperative and...	6
Monitoring CAR T cells in peri...	6
Emergence of Carbapenemase-pro...	5
Is there any association betwe...	5
Exploring eponyms in a corpus ...	5
LSM3, NDUFB3, and PTGS2 may be...	5
Evaluation of iron replacement...	5

Concept, Design & Programming
Dr. Adrian Man

Nr. 1(1)/2005

Clinical applications of total PSA and free PSA tumor markers

Adina Elena Stanciu

Abstract:

During the last 10 years the most widely used tumor marker for early detection of the prostate cancer was the prostate specific antigen (PSA). The concentration of total PSA in serum correlates with the volume of prostate cancer and changes in the levels reflect the disease process. It’s a very good relationship between serum total PSA, tumor size and stage of the disease. Total PSA is a sensitive serum marker for prostate cancer, but its specificity is limited by a high frequency of falsely elevated values in men with benign prostatic hyperplasia (BPH). Therefore, the determination of the proportion of the free PSA has become widely used to improve the can-cer specificity of total PSA, especially in men with PSA values in the “grey zone” (4-10 ng/ml). Free PSA values can help differentiate prostate cancer from BPH and reduce the number of unnecessary biopsies.

Keywords: total PSA,free PSA,prostate cancer,benign prostatic hyperplasia

Download full text PDF
(325 KB)

Stanciu AE. Clinical applications of total PSA and free PSA tumor markers . Rev Romana Med Lab. 2005;1(1):33-7